Meeting
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
Authors
Aditya Juloori
University of Chicago Medical Center, Chicago, IL
Aditya Juloori , Gregory Gan , Jun Zhang , Mohamed E. Abazeed , Jared H Hara , Andrew Baschnagel , Anne M. Traynor , Michael F. Bassetti , Marina Chiara Garassino , Jyoti D. Patel , Steven J. Chmura , Christine M. Bestvina
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05068232
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8615)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8615
Abstract #
TPS8615
Poster Bd #
234a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2023 ASCO Annual Meeting
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
First Author: Lionel Falchero
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2021 ASCO Annual Meeting
Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP)plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase.
First Author: Maria Rosario García Campelo